Aptevo Therapeutics Inc. (APVO) Stock Score, Valuation & Financial Research

Aptevo Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for APVO

Aptevo Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.80. These figures are a research snapshot, not a buy or sell recommendation.

What Aptevo Therapeutics Inc. does

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Aptevo Therapeutics is a clinical-stage biotechnology company that focuses on the research and development of novel immunotherapeutic candidates for cancer treatment. The company generates no commercial product revenue and relies on capital raises and financing activities to fund its ongoing clinical development programs and operational expenses.

Products and services

  • The company develops bispecific and trispecific immunotherapies using its proprietary ADAPTIR and ADAPTIR-FLEX modular protein technology platforms, with lead clinical candidates including mipletamig.

Brands and product families

  • ADAPTIR — Proprietary modular protein technology platform. Source
  • ADAPTIR-FLEX — Proprietary modular protein technology platform. Source

Customer types

Clinical trial participants and healthcare providers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials. Source

Business strengths to evaluate

  • Proprietary ADAPTIR and ADAPTIR-FLEX modular protein technology platforms Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing to continue operations Source
  • Risks associated with clinical trial success, regulatory approval, and manufacturing of complex biologics Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

APVO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.80
Market capitalization:
3.93M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -26.41M
Free cash flow:
USD -25.59M
Cash:
USD 9.8M
Total debt:
USD 4.21M
EPS:
USD -211.18

What stands out

  • Free cash flow is USD -25.59M, negative for the stored period.
  • The balance sheet shows USD 9.8M of cash versus USD 4.21M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 5.59M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for APVO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can APVO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is APVO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for APVO to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of APVO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research APVO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.